New biologic for chronic plaque psoriasis set to be PBS listed
A new targeted biologic for the estimated 19,000 Australian adults living with severe chronic plaque psoriasis will be listed on the Pharmaceutical Benefits Scheme (PBS) on 1 February 2019, for those who meet the reimbursement criteria.
ILUMYA™ (tildrakizumab) belongs to a new class of biologic medicines, known as interleukin (IL) inhibitors, that specifically block a protein called IL-23,3 an inflammatory substance known to play a key role in psoriasis. The treatment, which involves skin injections every 12 weeks, following an initial dose at day one and another dose at week four, can be stored outside a refrigerator for up to 30 days.
Click here to read an article from Associate Professor Peter Foley on the new drug.